WASHINGTON, Oct 30 (Reuters) - Only half of the people in the United States who most need immediate treatment for H1N1 swine flu are actually seeking it, even as the virus spreads at unprecedented speed, U.S. health officials said on Friday
Previously, the Obama administration blamed chicken eggs on too few (shortage) vaccines and now Obama is blaming Americans for not getting the vaccine.
First, how is it there was a shortage in vaccines when this new information that not enough Americans aren't getting the vaccine mesh together back in September and the beginning of October?
Did this new information on not enough Americans are getting the vaccine just happen overnight?
WASHINGTON (Reuters) – Nearly two-thirds of U.S. parents say they will hold off having their children vaccinated against the H1N1 swine flu or will not get them immunized at all, according to a survey released on Wednesday.
The findings, published by Consumer Reports, underscore one of the main challenges facing the Obama administration as it readies a massive swine flu vaccination roll-out -- how to persuade the most vulnerable people to protect themselves against the new virus.
That was back in September before there was a so-called shortage caused by the vaccine being produced by chicken eggs.
On September 27, Novartis also began shipments of the first doses of its influenza A(H1N1) 2009 monovalent vaccine to the United States. The early shipment is the first of an accelerated effort to provide as much A(H1N1) vaccine as soon as possible, despite the low yield seen with the initial production seed strain provided by the World Health Organization. Production has switched to a new higher yielding seed strain which will allow deliveries of higher volumes later in the year.
Novartis Influenza A(H1N1) 2009 monovalent vaccine was approved by the FDA on September 15, 2009. The A(H1N1) vaccine is an inactivated subunit vaccine approved for active immunization of persons 4 years of age and older, including patients with underlying chronic medical conditions. The US Department of Health and Human Services (HHS) awarded Novartis two contracts totaling USD 979 million for purchase of H1N1 bulk vaccine and the Novartis proprietary MF59 adjuvant.
When you consider the facts that the vaccine is being produced with using a cell-based method in Europe and the CDC said the targeted 2.4 million doses for the beginning week in October was met ; how was there a shortage when it was known in September that many Americans were not going to get the vaccine?
Jon Cohen: Hi, thanks. You said you had an anticipated schedule, can you tell us what it is or make it public. You said that right now, supply isn't meeting demand. Yet, that conflicted with requests for the 2.4 million doses, only being 2.2 million
Thomas Frieden: We can provide information and we will each Friday. It's information that changes day-to-day as manufacturers figure out how much is ready for shipping and to clarify, vaccine goes from the manufacturers to a central distributor, and from the central distributor, onward to providers or the health departments to actually vaccinate. I'm sorry, the second part of your question was about? Supply and demand. The 2.4 million available was the first 2.4 million doses. Some states were figuring out exactly where they wanted to spend or send those doses. So far nearly all of that 2.2 million has been called down. It will take some time to get the whole system from the manufacturer through the distributor, to the providers and to people who want to get vaccinated up and running. One of the things that this weekend and next, will provide a dry run. Not enough vaccine around. Although we wished we had more, some can get vaccinated. It will get us ready to get a running start on vaccination mid to late October.
Moreover, according to Anne Schuchat, M.D., 600,000 doses were not for "everyone".
“It’s a good vaccine, but it’s one that can’t be used in absolutely everyone,” said Rear Admiral Anne Schuchat, M.D., director, National Center for Immunization and Respiratory Diseases, during the H1N1 video briefing.
The initial shipment is live and administered by nasal spray, which isn't suitable for individuals with chronic underlying conditions or pregnant women — the priority group the CDC says is at greatest risk. The initial 600,000 doses will instead be directed toward health care workers.
What could have been the problem with a so-called shortage?
It wasn't because of the vaccine being produced with chicken eggs when it is known that the vaccine was being produced with using the cell-based method in Europe.
Could it be because (the CDC continues to deny the vaccine is mutating) the virus is mutating and vaccines that had been produced earlier be ineffective?
As was reported in Kenya, the WHO pointed to the vaccine being discarded because of the possibility that the virus could be mutating.
NAIROBI, Kenya, Oct 23 - The World Health Organisation (WHO) says that scientists have discarded a first set of vaccines that had been developed for the prevention of H1N1 influenza virus commonly known as swine flu.
WHO Country Director Dr David Okello said on Friday that this was because of the dilemma there was a possibility of the highly contagious virus mutating into a more severe form.
“The scientists have moved to the second level because of the dilemma we are all facing,” Dr Okello said.
He said if the virus mutated, the people who are developing the vaccine would have to advance their technologies to address the problem.
Why discard a vaccine if it's not mutating? That is because contrary to Jay Butler from the CDC comments that it isn't, it is.
In India, as pointed out on this site, Puna scientists were concerned that a more virulent virus was mutating.
Pathologists at the state-run Sassoon General Hospital in Pune took tissue samples from the bodies of the deceased to study the effect of the virus that attacks the respiratory tract. "Our doctors have concluded that the virus has undergone some genomic changes," said Dr Arun Jamkar, dean, BJ Medical College, Pune. A key discovery is that the virus, which was initially causing a bacterial infection, is now causing a more potent viral infection.
It is amazing what one day can make when an e-mail is sent to Puna linking to this site pointing to the article.
New[ name ]
Thu Oct 29 07:33:48 PM mail.google.com none used thomasalamb.blogspot
.com/2009/10/ferrets -india-and-physician s-mutating.html Go (3)
New[ name ]
Thu Oct 29 07:33:48 PM IP# **.**.***.** IP name : **.**.***.**.static.vsnl.net.in
IP owner : USED FOR STATIC BROADBAND CUSTOMERS IN PUNE India Pune Maharashtra
And then see what the Indian government comes out with the next day.
Pune: Cities like Pune and Bangalore will see many minor waves, instead of a more virulent second wave, of swine flu, according to Dr Vishwa Mohan Katoch, secretary, department of health research.
That is also the talking point with the CDC. Their denial on the virus mutating.
What about different vaccines for different groups?
As pointed out, 600,000 doses were being directed to health care workers and states were looking at making health care workers getting the vaccine mandatory, but even that plan had a glitch when health care workers protested getting the vaccine.
How can you have a shortage if health care workers are protesting mandates on getting the vaccine?
Since the vaccine for the H1N1 is being produced in Europe, what happened in places like Germany?
Lung specialist Wolfgang Wodarg has said that there are many risks associated with the vaccine for the H1N1 virus.
He has grave reservations about the firm Novartis who are developing the vaccine and testing it in Germany. The vaccination is injected “with a very hot needle”, Wodarg said.
The nutrient solution for the vaccine consists of cancerous cells from animals and "we do not know if there could be an allergic reaction".
But more importantly, some people fear that the risk of cancer could be increased by injecting the cells.
As pointed out on this site, the Obama administration paid Novartis millions of dollars to purchase the cell-based H1N1 vaccine from Novartis.
If specialists in Germany have a problem with the vaccine, should the Obama administration have a problem?
Moreover, adding to the problem in Germany, two different vaccines are being given to government officials and the public.
One might think that the arrival in Germany of the first of 50 million doses of swine flu vaccine on Monday might be cause for celebration. But with news breaking over the weekend that top government officials in Berlin will be injected with an alternative vaccine -- one widely seen as safer -- a debate about an alleged two-class medical system has erupted.
Going back to the first week in October, adding to this so called shortage because of the chicken egg, were the distribution methods
Health authorities have acknowledged that the pace of distribution is not fast enough based on the population's demands. They are working with what is currently available and suggest that an ample supply of vaccine will be readily available by mid-October.
As an aside, I pointed to Jay Butler in this post and stated in part:
For Sarah Palin, she is fortunate that Butler didn't join her administration when you consider Butler was going to testify against Palin's support of Alaska's parental consent law.
That should tell you the agenda Butler has.
And that brings me to the following comments I am making that the Obama administration through Jay Butler is misinforming the public that the virus isn't mutating when you look at drug companies who are responding to the mutation by developing vaccines to combat the mutation.
A few days ago, a source who works at Alaska's Providence Hospital stated 3 children who were less than 5 years old died from complications that mirrored what was stated in Puna India prior to the Indian government's statement con tray to scientists' concerns that the virus has mutated.
Nothing can be confirmed on the cause, but given what is being published today on deaths of children and vaccines made by companies like Novartis were being sent to the U.S in September, this should cause the news media to scrutinize what the Obama administration is telling the public.
Oct. 30 (Bloomberg) -- Swine flu has killed 114 children in the U.S. since the outbreak surfaced in April, including 19 reported in the week from Oct. 18 to Oct. 24, the Centers for Disease Control and Prevention said today on its Web site.
The number of children confirmed to have died from the virus, also known as H1N1 influenza, rose 20 percent from the 95 reported Oct. 23 by the CDC. Swine flu killed 530 people from Aug. 30 to Oct. 24 and accounted for 12,466 hospitalizations, according to the Atlanta-based agency’s Web site. The mortality data come from 28 states.
The investigative reporting is lacking on the topic if the virus has mutated. And arguably it is because most of the media is favorable to the Obama administration and does not want to run contrary to what the talking points coming from Obama are on the H1N1 topic.
However, there are some who question the safety of the vaccine and parental rights.
When it came to being against parental rights, Jay Butler is the one who opposed Palin on the topic and he heads up the H1N1 vaccine program and we also know how the Obama administration views parental rights.
With the health care emergency being issued by Obama, will parents be required to get their children vaccinated against the H1N1? That remains to be seen.
When it comes to the health care issue, it should be clear the the Obama administration has handled the H1N1 pandemic poorly. So people should be concerned on how the Obama administration will handle health care reform to include the government's vaccination program.